Two different devices, 1 self-expanding and 1 balloon-expandable, have been developed for patients who underwent transcatheter aortic valve implantation with contrasting data about efficacy and safety. Pubmed, Medline, and Google Scholar were systematically searched for studies of these different devices, with data derived from randomized controlled trial or registries with multivariate analysis. All-cause death at 30 days and at follow-up were the primary end points, whereas postprocedural moderate or severe aortic regurgitation (AR), stroke, major vascular complications, bleedings, and pacemaker implantation the secondary ones. Six studies with 957 self-expanding and 947 balloonexpandable valves were included: 1 randomized controlled trial and 5 observational studies. At 30 days follow-up, rates of death did not differ between self-expanding and balloon-expandable valves (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.47 to 1.17), whereas balloon expandable reduced rates of moderate or severe AR (OR 0.51, 95% CI 0.27 to 0.99) and of pacemaker implantation (OR 0.28, 95% CI 0.17 to 0.47). After a follow-up of 360 days (300 to 390), rates of all-cause death did not differ between the 2 groups. In conclusion, risks of moderate or severe AR and pacemaker implantation were lower with the balloon-expandable devices without an impact on 30 days and midterm mortality. Ó 2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;115:1720e1725)
Although self-expanding devices expose patients to more frequent pacemaker implantations, with increased costs but without a negative impact on prognosis, 8 contrasting data have been reported about postimplant aortic regurgitation (AR), one of the most common complications of TAVI, with a welldefined impact on prognosis. 9 Recently, some registries have demonstrated an increased risk of AR for patients treated with self-expanding devices 10, 11 as subsequently confirmed by a single randomized controlled trial. 12 These studies, however, are limited by small sample size, not allowing conclusive appraisal about the most efficacious and safe device for patients with TAVI. Consequently, we performed a meta-analysis of randomized controlled trials and adjusted observational studies to compare self-expanding and balloon-expandable devices.
Methods
The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) amendment to the Quality of Reporting of Meta-analyses statement and recommendations from the Cochrane Collaboration and Meta-analysis of Observational Studies in Epidemiology were followed during the development of the present systematic review.
Pertinent articles were searched for in Medline, Cochrane Library, Biomed Central, and Google Scholar without time limit (up to June 4, 2014) in keeping with established methods with Medical Subject Headings (MeSH) strategy and with the following terms, including "TAVI" or "transcatheter aortic valve implantation" or "self-expandable" or "balloon expandable" or "Corevalve" or "Edwards."
Two independent reviewers (FDA and GBZ) screened the retrieved citations through the title and/or abstract, and divergences were resolved through consensus. If potentially pertinent, studies were then appraised as complete reports according to the following explicit selection criteria. Studies were included if (i) they reported outcomes of patients with TAVI treated with self-expanding or balloon-expandable techniques and (ii) randomized controlled trials or observational studies adjusted with multivariate analysis, whereas exclusion criteria were (i) nonhuman setting and (ii) duplicate reporting (in which case the manuscript reporting the largest sample of patients was selected).
Two independent reviewers (FDA and GBZ) abstracted the following data on prespecified forms: authors, journal, year of publication, location of the study group, and baseline clinical and interventional features. Data extraction was conducted by mutual agreement, and all potential disagreements were resolved by consensus. All-cause death at 30 days and at follow-up were the primary end points, whereas postprocedure moderate or severe AR, stroke, major vascular complications and bleedings, and pacemaker the secondary ones.
Continuous variables are reported as mean (SD) or median (interquartile). Categorical variables are expressed as n/ N (%). Statistical pooling was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Pairwise meta-analysis was performed for overall studies, whereas meta-regression analysis was performed to test the effect of baseline features on primary and secondary outcomes. The study was approved by an institutional review committee and that the subjects gave informed consent.
Results
After literature search, 8 full texts were evaluated for inclusion into review: 2 were excluded as they did not report on outcomes adjusted through multivariate analysis 16, 17 and finally 6 studies were included 7,10e12,18,19 (Figure 1 ). All the studies were multicenter, with a single randomized controlled trial, all of them exploiting balloonexpandable devices of 23 and 26 mm and self-expanding devices of 23, 26, 29, and 31 mm (Tables 1 and 2) .
Overall, 957 self-expandable and 947 balloonexpandable valves were included, with a median age of 82 (81 to 83) years, 42% (36 to 53) of them being women, with a median logistic EuroSCORE of 22 (21 to 
Discussion
To the best of our knowledge, this is the largest study comparing balloon-expandable and self-expanding devices for patients with TAVI, demonstrating that (a) balloonexpandable prosthesis reduced the rates of moderate and severe AR and of pacemaker implantation; and (b) rates of 30 and 360 days death did not vary.
AR represents one of the most common complications for patients with TAVI.
20e22 Balloon-expandable valves reduced risk of AR compared with self-expanding valves, in studies exploiting second and third generations of currently available devices.
Our results confirmed in a larger population those derived from the only randomized controlled trial on the topic included in the present analysis. 12 Many different explanations have been provided. Burden of aortic calcification may play a crucial role because it may reduce the complete sealing of the paravalvular space. This may be particularly relevant for self-expanding valves, which were recently demonstrated to be inferior regarding radial force, 23 especially for patients with a large angle between ascending aorta and left ventricle outflow tract because of their longer size. 24 Similarly, the results of the meta-regression analysis demonstrated an increased superiority for balloon-expandable devices in Valvular Heart Disease/Basic Features of Included Studieslarger diameters, probably related to similar reasons. It should be remembered, however, that AR remains difficult to be assessed.
Implantation of a self-expanding valve has been related to higher rates of atrioventricular blocks requiring a pacemaker. This result is confirmed in the present study and may be explained because of the different valve designs. The self-expanding prosthesis has a stabilizing nitinol frame that exerts greater radial forces on the left bundle branch, which runs superficially just below the endocardium in the uppermost part of the leftward ventricular septum. 25 To maintain hemodynamic efficacy, the frame of the selfexpanding valve is dependent on its firm self-expansion to avoid recoil and paravalvular regurgitation, and ongoing compressive forces are needed to achieve greater prosthetic stability. Although this complication does not affect prognosis, 8 it may increase costs and length of hospitalizations, as the hazard of subsequent complications. 26, 27 Figure 2 . Rates of inhospital complications-all-cause death at 30 days and at follow-upinballoon-expandableandself-expandablevalves.PM¼pacemaker implantation.
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No differences for stroke were reported in the present analysis with balloon-expandable devices. Catheter manipulations of the calcified and diseased aortic valve may cause embolization of aortic debris or thrombotic material resulting in stroke or TIA, 28 ,29 but this does not appear to depend on differences between self-or balloon-expandable devices.
Thirty-day and 1-year death rates did not differ between the 2 valves. Many explanations may be provided: although higher rates of AR may exert a detrimental effect on prognosis for patients treated with self-expanding devices, follow-up is still limited (no >1 year) not allowing definitive conclusions. The present analysis has many limitations. From a methodologic point of view, we included both observational studies, although adjusted with multivariate analysis, and randomized controlled trials, consequently dealing with different level of evidence. Moreover, from a clinical point of view, in each study, AR was assessed through echocardiography, with the well-known limitations of this operatordependent assessment and without an independent core laboratory assessing AR. Finally, in each study, outcomes were reported with Valve Academic Research Consortium (VARC) definition increasing reproducibility of these results.
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